PHIO - Phio gets monitoring panel's nod to advance enrolling in skin cancer trial after data review
- Phio Pharmaceuticals ( NASDAQ: PHIO ) said an independent Data Monitoring Committee (DMC) recommended proceeding to the enrollment of the next dose group after reviewing interim safety data from a phase 1b trial of PH-762 to treat advanced melanoma.
- After completing the treatment period through excision of the tumor, safety data from the initial group of three people in the phase 1 trial was evaluated by the DMC.
- The company noted that safety data review disclosed no dose-limiting toxicity, and no drug-related severe adverse events or serious adverse events, and thus the DMC recommended proceeding to the enrollment of the subsequent dose group.
- The trial is ongoing at the Gustave Roussy Institute in Villejuif, France. The trial expected to enroll up to 21 patients with advanced melanoma — a type of skin cancer.
- Phio expects to start a U.S. phase 1b trial focusing on treating cutaneous squamous cell carcinoma (cSCC) and other selected cutaneous malignancies, early in the H2 2023.
- PHIO -0.32% to $6.23 premarket Feb. 10
For further details see:
Phio gets monitoring panel's nod to advance enrolling in skin cancer trial after data review